Case Report
Copyright ©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Hepatol. Jun 27, 2013; 5(6): 332-335
Published online Jun 27, 2013. doi: 10.4254/wjh.v5.i6.332
Coadministration of telaprevir and transcatheter arterial chemoembolization in hepatitis C virus-associated hepatocellular carcinoma
Harrys A Torres, Parag Mahale, Ethan D Miller, Thein H Oo, Catherine Frenette, Ahmed O Kaseb
Harrys A Torres, Parag Mahale, Departments of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States
Ethan D Miller, Departments of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States
Thein H Oo, Section of Benign Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States
Catherine Frenette, Liver Transplantation, Weill Cornell Medical College, The Methodist Hospital, Houston, TX 77030, United States
Ahmed O Kaseb, Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States
Author contributions: Torres HA, Miller ED, Oo TH, Frenette C and Kaseb AO provided care to the patient and designed the study; Mahale P collected the data; Torres HA, Miller ED, Oo TH, Frenette C and Kaseb AO analyzed and interpreted the data; Torres HA and Mahale P drafted the manuscript; Torres HA, Mahale P, Miller ED, Oo TH, Frenette C and Kaseb AO provided critical revision of the manuscript for important intellectual content.
Correspondence to: Harrys A Torres, MD, FACP, Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, United States. htorres@mdanderson.org
Telephone: +1-713-7926830 Fax: +1-713-746839
Received: March 2, 2013
Revised: May 1, 2013
Accepted: May 17, 2013
Published online: June 27, 2013
Processing time: 117 Days and 11.5 Hours
Abstract

The use of direct-acting antiviral agents (e.g., telaprevir, boceprevir) has improved response rates in patients with hepatitis C virus (HCV) genotype 1 infections. Substantial number of drug-drug interactions are anticipated with the use of telaprevir, a cytochrome P450 3A and P-glycoprotein substrate and inhibitor. Herein we describe a patient with HCV-associated hepatocellular carcinoma treated simultaneously with a telaprevir-containing regimen and localized chemotherapy (transcatheter arterial chemoembolization) with doxorubicin. No clinically relevant interactions or adverse events developed while on antiviral therapy.

Keywords: Hepatitis C virus; Cancer; Hepatocellular carcinoma; Transcatheter arterial chemoembolization; Telaprevir; Interactions

Core tip: This case suggests that therapy for chronic hepatitis C virus (HCV) infection may be given simultaneously with localized chemotherapy in patients with hepatocellular carcinoma (HCC). The use of telaprevir has improved response rates in patients with HCV genotype 1 infections. Substantial number of drug-drug interactions are anticipated with the use of telaprevir, a cytochrome P450 3A and P-glycoprotein substrate and inhibitor. Herein, we describe a patient with HCV-associated HCC treated simultaneously with a telaprevir-containing regimen and localized chemotherapy (transcatheter arterial chemoembolization). No clinically relevant interactions or adverse events developed while on antiviral therapy.